NCBP2L

Across TCGA pan-cancer cohorts, NCBP2L Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated NCBP2L data layer compared with 15 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher NCBP2L Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NCBP2L expression acts as an unfavorable survival marker.

SKCM and BLCA are the cancer types where NCBP2L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	II,III,IV	0.087	0.708	<.001	9	view →
BLCA	OS	Median	All	0.249	0.709	.042	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

NCBP2L–SKCM (DFS)

Open the SKCM breakdown →